🔗 Visit the ClinicalTrials.gov page for NCT00627042
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | HCC and angiogenesis: possible targets and future directions. | Nat Rev Clin Oncol | 2011 | 2.10 |
| 2 | Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. | Oncotarget | 2012 | 1.55 |
| 3 | Clinical advances in the development of novel VEGFR2 inhibitors. | Ann Transl Med | 2014 | 1.24 |
| 4 | Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. | PLoS One | 2013 | 0.88 |
| 5 | Targeting the tumor stroma in hepatocellular carcinoma. | World J Hepatol | 2015 | 0.86 |
| 6 | Targeted therapies in the treatment of advanced hepatocellular carcinoma. | Clin Med Insights Oncol | 2013 | 0.83 |
| 7 | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. | Oncoimmunology | 2015 | 0.77 |